<HTML>
<HEAD>
<TITLE>LabOne, Inc. Form 8-K dated December 3, 2003</TITLE>
</HEAD>
<BODY>

<FONT SIZE=5><STRONG><P ALIGN="CENTER">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</P>
</FONT></STRONG><FONT SIZE=4><P ALIGN="CENTER">Washington, D.C. 20549</P>
</FONT><FONT SIZE=5><STRONG><P ALIGN="CENTER">FORM 8-K</P>
</FONT></STRONG><P ALIGN="CENTER">CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>
<P ALIGN="CENTER">Date of Report: <U>December 3, 2003</P>
</U><P ALIGN="CENTER">Commission file number: 0-16946</P>
<B><U><FONT FACE="Times,Times New Roman" SIZE=5><P ALIGN="CENTER">LabOne, Inc.</P>
</B></U></FONT><P ALIGN="CENTER">10101 Renner Blvd.</P>
<P ALIGN="CENTER">Lenexa, Kansas 66219</P>
<P ALIGN="CENTER">(913) 888-1770</P>
<FONT FACE="Times,Times New Roman"><P ALIGN="CENTER">Incorporated in Missouri</P>
<P ALIGN="CENTER">I.R.S. Employer Identification Number: 43-1039532</P>
</FONT><FONT FACE="Times,Times New Roman" SIZE=2><P>&nbsp;</P>
</FONT><P><HR ALIGN="RIGHT"></P>


<FONT FACE="Times,Times New Roman"><P>Item 9.&nbsp;&nbsp;Regulation FD Disclosure</P>
</FONT><P ALIGN="CENTER"><B>LabOne Establishes Earnings Guidance for 2004

</B></P>

<P>LabOne, Inc. (Nasdaq: LABS), announced today its earnings guidance for fiscal year 2004 of $1.40 per diluted share.  The guidance follows the review of the Company's budget plan by the board of directors on November 19, 2003, and does not include the impact of any contemplated acquisitions.</P>

<P><B>Forward-looking Statements</B></P>

<P>Statements made in this report that are not historical facts are "forward-looking statements," including, but not limited to, projections and statements of future earnings. The Company's future results of operations may differ materially from those expressed in these forward-looking statements. Many factors could cause actual results to differ materially from those that may be expressed or implied in such forward-looking statements, including, but not limited to, the volume, mix and pricing of laboratory tests and other services provided by the Company, competition and the significantly greater financial and other resources available to competitors, the Company's ability to execute its growth strategy which includes acquiring ongoing businesses and entering into strategic alliances, the availability on reasonable terms of acquisition candidates and of additional debt and equity financing to finance acquisitions, the ability of the Company to successfully integrate acquisitions, government reimbursement policies, the loss of one or more significant customers, natural disasters or other interruptions to the Company's ability to provide testing services at its testing facilities, general economic conditions, the cash generated by the Company's operations and from other financing sources, and other factors detailed from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including the Cautionary Statement filed as Exhibit 99 to the Company's Annual Report on Form 10-k. Investors are cautioned not to put undue reliance on any forward-looking statement.</P>


<P>&nbsp;</P>
<P>&nbsp;</P>
</DIR>

<P><HR></P>
<P>&nbsp;&nbsp;</P>
<I><FONT SIZE=5><P ALIGN="CENTER">Signature</I></FONT><FONT FACE="Times,Times New Roman"> </P>
<P ALIGN="CENTER">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P ALIGN="CENTER">&nbsp;</FONT><FONT SIZE=5>LabOne, Inc.</P>
</FONT>
<CENTER>
<TABLE cellSpacing=0 cellPadding=10 width=524 border=0>
  <TR>
    <TD vAlign=top width="40%">
      <P>Date:&nbsp;&nbsp;December 3, 2003</P></TD>
    <TD vAlign=center width="60%">
      <P>By <U>/s/ <I>Joseph C. Benage</I></U><BR>Joseph C. Benage
      <BR>Executive V.P. and Secretary
  </P></TD></TR>
</TABLE></CENTER>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "htm8k12.htm", "secsgml_size_bytes": 3976}]
{"company-data": {"conformed-name": "LABONE INC/", "cik": "0000830158", "assigned-sic": "8071", "irs-number": "431039532", "state-of-incorporation": "MO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-92137", "film-number": "031033944"}, "business-address": {"street1": "10101 RENNER BLVD", "street2": "P. O. BOX 7568", "city": "LENEXA", "state": "KS", "zip": "66219", "phone": "9138881770"}, "mail-address": {"street1": "10101 RENNER BLVD", "street2": "X", "city": "LENEXA", "state": "KS", "zip": "66219"}, "former-company": [{"former-conformed-name": "LAB HOLDINGS INC", "date-changed": "19980406"}, {"former-conformed-name": "SEAFIELD CAPITAL CORP", "date-changed": "19920703"}, {"former-conformed-name": "SEAFIELD CAPTIAL CORP", "date-changed": "19910520"}]}
LabOne, Inc. Form 8-K dated December 3, 2003
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report:
December 3, 2003
Commission file number: 0-16946
LabOne, Inc.
10101 Renner Blvd.
Lenexa, Kansas 66219
(913) 888-1770
Incorporated in Missouri
I.R.S. Employer Identification Number: 43-1039532
Item 9.  Regulation FD Disclosure
LabOne Establishes Earnings Guidance for 2004
LabOne, Inc. (Nasdaq: LABS), announced today its earnings guidance for fiscal year 2004 of $1.40 per diluted share.  The guidance follows the review of the Company's budget plan by the board of directors on November 19, 2003, and does not include the impact of any contemplated acquisitions.
Forward-looking Statements
Statements made in this report that are not historical facts are "forward-looking statements," including, but not limited to, projections and statements of future earnings. The Company's future results of operations may differ materially from those expressed in these forward-looking statements. Many factors could cause actual results to differ materially from those that may be expressed or implied in such forward-looking statements, including, but not limited to, the volume, mix and pricing of laboratory tests and other services provided by the Company, competition and the significantly greater financial and other resources available to competitors, the Company's ability to execute its growth strategy which includes acquiring ongoing businesses and entering into strategic alliances, the availability on reasonable terms of acquisition candidates and of additional debt and equity financing to finance acquisitions, the ability of the Company to successfully integrate acquisitions, government reimbursement policies, the loss of one or more significant customers, natural disasters or other interruptions to the Company's ability to provide testing services at its testing facilities, general economic conditions, the cash generated by the Company's operations and from other financing sources, and other factors detailed from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including the Cautionary Statement filed as Exhibit 99 to the Company's Annual Report on Form 10-k. Investors are cautioned not to put undue reliance on any forward-looking statement.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
LabOne, Inc.
Date:  December 3, 2003
By
/s/
Joseph C. Benage
Joseph C. Benage
Executive V.P. and Secretary